12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

• ClinicalTrials.gov Identifier: NCT01623310
• Recruitment Status: Completed
• First Posted: June 19, 2012
• Results First Posted: January 24, 2018
• Last Update Posted: January 24, 2018
• Sponsor: Optinose US Inc.
• Information provided by (Responsible Party): Optinose US Inc.

Study Description

Brief Summary:

This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The duration of each subject's participation is approximately 53 weeks.

Condition or disease	Intervention/treatment	Phase
Nasal Polyps	Drug: Fluticasone Propionate	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 223 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: 12-Month OL Evaluating the Safety of Intranasal Administration Fluticasone BID Using OptiNose Device in Subjects With CS With or Without Nasal Polyps
• Study Start Date: September 2013
• Actual Primary Completion Date: August 2015
• Actual Study Completion Date: October 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: OPN-375 400 μg BID; OPN-375 400 μg BID for 12 months	Drug: Fluticasone Propionate; Using Optinose Exhalation Delivery System; Other Name: OPN-375

Outcome Measures

Primary Outcome Measures :

1. Adverse Events [ Time Frame: 12 Months ]
   Patients with at least one Adverse Events

Secondary Outcome Measures :

1. Sinonasal Outcome Test 22 (SNOT-22) Total Score [ Time Frame: Baseline, Month 3, Month 12 ]

   Change from baseline to Month 3 & Month 12 in SNOT-22 Total Score

   SNOT-22 is validated in large populations with chronic sinusitis with and without nasal polyps. The 22 questions are used to calculate a total score (the sum of all items) and 4 subscale scores. The 22 questions are divided among 4 subscales: Rhinologic, Ear and Facial Symptoms, Sleep Function, and Psychological Issues subscales. The total score can range from 0-110, 0 being the best and 110 being the worst.

   0: No problem

   1. Very mild problem
   2. Mild or slight problem
   3. Moderate problem
   4. Severe problem
   5. Problem as bad as it can be
2. Lund-Mackay Total Score [ Time Frame: Baseline, Month 3, Month 12 ]

   Change from baseline to Month 3, Month 12, in Lund-Mackay Total Score

   Lund-Mackay Assessment of nasal cavity appearance, via nasoendoscopy, used to evaluate signs of edema, discharge, crusting, scarring/adhesions, and nasal polyps, with each sign rated on a 0 to 2 scale 0: None 2: Worse outcome

3. Patient Global Impression of Change (PGIC) [ Time Frame: Baseline, Month 3, Month 12 ]
   The PGIC took less than 1 minute to complete. Subjects answered question, "Since starting the study drug, how would you rate the change in your symptoms?" Patients may answer very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data listed below reports the total number of patients who answered very much improved, much improved, or minimally improved at the specified time.
4. Summed Bilateral Nasal Polyp Grading Scale Score [ Time Frame: Baseline, Month 3, Month 12 ]

   In subjects with nasal polyps, polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy.

   0: No polyps

   1. Mild polyposis: polyps not reaching below the inferior of the middle turbinate
   2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
   3. Severe polyposis: large polyps reaching below the lower inferior border of the inferior turbinate
5. Nasal Polyp Surgery Eligibility [ Time Frame: Baseline, Month 3, Month 12 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Men or women aged 18 years and older Women must

  • be practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
  • be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or
  • be postmenopausal (spontaneous amenorrhea for at least 1 year).
• Women of child-bearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the screening visit
• Have either:

a history of chronic sinusitis with bilateral nasal polyposis determined by nasoendoscopy at screening visit OR a history of chronic sinusitis (without polyps) for equal to or greater than 12 weeks and currently experiencing 2 or more of the following symptoms, one of which MUST be either nasal blockage/congestion or nasal discharge (anterior and/or posterior nasal discharge):

1. nasal blockage/congestion
2. nasal discharge (anterior and/or posterior nasal discharge)
3. facial pain or pressure

4. reduction or loss of smell

   • Subjects with comorbid asthma or COPD must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral steroid use)within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent; See Attachment 1) for at least 3 months before screening with plans to continue use throughout the study.
   • Must be able to cease treatment with intranasal steroids and inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit
   • Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at the screening visit, see Section 12.1, Visit 1, screening procedures.
   • Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

• Women who are pregnant or lactating
• Inability to have each nasal cavity examined for any reason, including nasal septum deviation
• Nasal septum perforation
• Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit
• Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasoendoscopy
• History of sinus or nasal surgery within 6 months before the screening visit
• Current, ongoing rhinitis medicamentosa (rebound rhinitis)
• Have significant oral structural abnormalities, eg, a cleft palate
• Diagnosis of cystic fibrosis
• History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
• Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution
• Planned sinonasal surgery during the period of the study
• Allergy, hypersensitivity, or contraindication to corticosteroids or steroids
• Allergy or hypersensitivity to any excipients in study drug
• Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or COPD
• Have nasal candidiasis
• Have taken a potent CYP3A4 inhibitor within 14 days before the screening visit; examples of these medications can be found in Section 11.6, Concomitant Medication.
• History or current diagnosis of any form of glaucoma or ocular hypertension (ie, intraocular pressure >21 mmHg)
• History of intraocular pressure elevation on any form of steroid therapy
• History or current diagnosis of the presence (in either eye) of a cataract
• Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
• A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
• Positive urine drug screen at screening visit for drugs of abuse (see Section 14.5), with the exception of prescribed medications for legitimate medical conditions
• Have participated in a previous clinical trial of OPTINOSE FLUTICASONE
• Have participated in an investigational drug clinical trial within 30 days of the screening visit
• Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator

Contacts and Locations

Locations

United States, Alabama

Achieve Clinical Research

Birmingham, Alabama, United States, 35216

United States, Florida

PAB Clinical Research

Brandon, Florida, United States, 33511

United States, Illinois

Sneeze Wheeze and Itch Associates

Normal, Illinois, United States, 61761

United States, Kansas

Professional Research Network of Kansas

Wichita, Kansas, United States, 67203

United States, Louisiana

Best Clinical Trials

New Orleans, Louisiana, United States, 70115

United States, North Carolina

PMG Research of Winston Salem

Winston-Salem, North Carolina, United States, 27103

United States, Ohio

HCCA Clinical Research Solutions

Middleburg Heights, Ohio, United States, 44130

United States, Oregon

Allergy and Asthma Research Group

Eugene, Oregon, United States, 97401

United States, Tennessee

Clinical Research Solutions

Franklin, Tennessee, United States, 37064

United States, Texas

William Blake Partners

Grapevine, Texas, United States, 76051

United States, Utah

Focus Clinical Research

Draper, Utah, United States, 84020

InterMountain Ear Nose and Throat

Salt Lake City, Utah, United States, 84102

Advanced Clinical Research

West Jordan, Utah, United States, 84088

United States, Washington

Premier Clinical Research

Spokane, Washington, United States, 99204

United States, West Virginia

Exemplar Research

Fairmont, West Virginia, United States, 26554

United States, Wisconsin

Allergy Asthma and Sinus Center

Greenfield, Wisconsin, United States, 53228

Sponsors and Collaborators

Optinose US Inc.

More Information

• Responsible Party: Optinose US Inc.
• ClinicalTrials.gov Identifier: NCT01623310
• Other Study ID Numbers: OPN-FLU-CS-3203
• First Posted: June 19, 2012
• Results First Posted: January 24, 2018
• Last Update Posted: January 24, 2018
• Last Verified: January 2018

Additional relevant MeSH terms:

Nasal Polyps; Polyps; Pathological Conditions, Anatomical; Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Fluticasone; Xhance; Anti-Inflammatory Agents; Bronchodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Asthmatic Agents; Respiratory System Agents; Dermatologic Agents; Anti-Allergic Agents